Robert A. Hegele

Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients.

Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.

Hypertriglyceridemia.

The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Sequencing: the next generation--what is the role of whole-exome sequencing in the diagnosis of familial cardiovascular diseases?

Exome sequencing identifies NFS1 deficiency in a novel Fe-S cluster disease, infantile mitochondrial complex II/III deficiency.

LipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias.

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.

Inducing thyrotoxicosis in the liver to treat raised cholesterol.

Simple genetics language as source of miscommunication between genetics researchers and potential research participants in informed consent documents.

The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Exome sequencing: new insights into lipoprotein disorders.

Linkage analysis and exome sequencing identify a novel mutation in KCTD7 in patients with progressive myoclonus epilepsy with ataxia.

Is plant-based cardioprotection evidence-based?

G-protein estrogen receptor as a regulator of low-density lipoprotein cholesterol metabolism: cellular and population genetic studies.

Treatment of severe hypertriglyceridaemia--authors' reply.

The effect of infrequent low-dose rosuvastatin on the lipid profile.

Canadian Cardiovascular Society position statement on familial hypercholesterolemia.

Congenital sucrase-isomaltase deficiency: identification of a common Inuit founder mutation.

Doctor my eyes: a statin-cataract connection?

A novel LIPE nonsense mutation found using exome sequencing in siblings with late-onset familial partial lipodystrophy.

Hypertriglyceridemia in the genomic era: a new paradigm.

A novel MC4R mutation associated with childhood-onset obesity: A case report.

A homozygous PMS2 founder mutation with an attenuated constitutional mismatch repair deficiency phenotype.

HDL re-examined.

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.

Chylomicronaemia--current diagnosis and future therapies.

The new dyslipidemia guidelines: what is the debate?

Cardiology patient page. Statin intolerance.

The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease.

Incident Diabetes With Statins: Biology, Artifact, or Both?

Erratum to: Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease.

Old gene, new phenotype: mutations in heparan sulfate synthesis enzyme, EXT2 leads to seizure and developmental disorder, no exostoses.

Trial Watch: Antisenses working overtime in lipids.

Severe Hypertriglyceridemia due to a novel p.Q240H mutation in the Lipoprotein Lipase gene.

Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council.

Finding the Therapeutic Sweet Spot: Using Naturally Occurring Human Variants to Inform Drug Design.

Combined hyperlipidemia: familial but not (usually) monogenic.

Novel therapeutics in hypertriglyceridemia.

Integrated Measure for Atherogenic Lipoproteins in the Modern Era: Risk Assessment Based on Apolipoprotein B.

Statin Safety in Chinese: A Population-Based Study of Older Adults.

Improving the Monitoring and Care of Patients With Familial Hypercholesterolemia.

Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?

Applying Atherosclerotic Risk Prevention Guidelines to Elderly Patients: A Bridge Too Far?

Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.

Rare Genetic Variants and High-Density Lipoprotein: Marching to a Different Drum.

Proprietary Considerations in the Use of Cardiovascular Genetic Data.

Targeted exonic sequencing of GWAS loci in the high extremes of the plasma lipids distribution.

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.

Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol.

Complying With the National Institutes of Health Guidelines and Principles for Rigor and Reproducibility: Refutations.

Whole-genome sequencing in French Canadians from Quebec.

Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes.

PCSK9: Regulation and Target for Drug Development for Dyslipidemia.

Genetic Confirmation Rate in Clinically Suspected Maturity-Onset Diabetes of the Young.

New oral agents for treating dyslipidemia.

Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically.

Lomitapide for the treatment of hypertriglyceridemia.

Seeking 'meta guidelines' for lipids.

PCSK9 inhibition and diabetes: turning to Mendel for clues.

Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters.

KMT2D p.Gln3575His segregating in a family with autosomal dominant choanal atresia strengthens the Kabuki/CHARGE connection.

The Ontario Neurodegenerative Disease Research Initiative (ONDRI).

Clinical utility gene card for: Sitosterolaemia.

Genetics for the Identification of Lipid Targets Beyond PCSK9.

Variants in ANGPTL4 and the Risk of Coronary Artery Disease.

Functional foods and dietary supplements for the management of dyslipidaemia.

Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants.

A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis.

Barriers to the Implementation of Lipoprotein Apheresis in Canada.

Genetics of Lipid and Lipoprotein Disorders and Traits.

Treatment of Severe Hypercholesterolemia in a Woman With Advanced Primary Sclerosing Cholangitis.

Heterozygous familial hypercholesterolemia presenting as chylomicronemia syndrome.

Insulin affordability.

Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults.

PCSK9 inhibitors: smooth sailing or a little turbulence ahead?

Recent advances in genetic testing for familial hypercholesterolemia.

Genetics of Triglycerides and the Risk of Atherosclerosis.

Clinical utility gene card for: Tangier disease.

Lomitapide for the treatment of hypercholesterolemia.

Tools for Enhancement and Quality Improvement of Peer Assessment and Clinical Care in Endocrinology and Metabolism.

HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology.

Clinical Validation of Copy Number Variant Detection from Targeted Next-Generation Sequencing Panels.

Polygenic determinants in extremes of high-density lipoprotein cholesterol.

Use of next-generation sequencing to detectgene copy number variation in familial hypercholesterolemia.

The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation.

Recent Advances in the Genetics of Atherothrombotic Disease and Its Determinants.

ARHGEF28 p.Lys280Metfs40Ter in an amyotrophic lateral sclerosis family with a C9orf72 expansion.

Identification of a novel synaptic protein, TMTC3, involved in periventricular nodular heterotopia with intellectual disability and epilepsy.

Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe.

OPTN p.Met468Arg and ATXN2 intermediate length polyQ extension in families with C9orf72 mediated amyotrophic lateral sclerosis and frontotemporal dementia.

Food Effect on Rosuvastatin Disposition and Low-Density Lipoprotein Cholesterol.

The ONDRISeq panel: custom-designed next-generation sequencing of genes related to neurodegeneration.

A Novel Generalized Lipodystrophy-Associated Progeroid Syndrome Due to Recurrent Heterozygous LMNA p.T10I Mutation.

Nutraceuticals in 2017: Nutraceuticals in endocrine disorders.

Ezetimibe prescriptions in older Canadian adults after an acute myocardial infarction: a population-based cohort study.

Learning From Patients With Ultrarare Conditions: Cholesterol Hoof Beats.

Secondary causes of chylomicronemia: defining the underside of the iceberg.

Whole genome sequencing in the clinic: empowerment or too much information?

The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes.

Fatty liver in a non-obese patient.

Complex genetic architecture in severe hypobetalipoproteinemia.